Abstract
Camptothecins are still among the most widely prescribed and effective anticancer drugs. Unfortunately, important drawbacks including water insolubility, lactone instability, reversibility of the drug–target interaction, drug resistance and toxicity are responsible for treatment failure and often require suspension of the drug administration itself. In order to overcome such drawbacks, several options in chemical manipulation of natural camptothecin have been explored, and effective compounds have been identified in a novel series of 7- oxyiminomethyl derivatives. Among the compounds of this series, the hydrophilic derivative namitecan (7 (2-aminoethoxy) iminomethyl camptothecin) has been selected for further development. The relevant features of namitecan are: 1) marked cytotoxic potency - likely related to multiple factors, including i) a potent inhibition of topoisomerase I, ii) a persistent stabilization of the cleavable complex, iii) an increased intracellular accumulation, and iv) a peculiar subcellular localization; 2) enhanced lactone stability and favorable pharmacokinetics; 3) remarkable antitumor efficacy in a large panel of human tumor xenografts (including tumor models relatively resistant to topotecan and irinotecan), particularly on squamous cell carcinomas. The clinical development of namitecan is currently ongoing. Namitecan exhibited an acceptable toxicity profile, with neutropenia being the dose-limiting toxic effect, and clinical benefit was appreciable in patients with different tumor types, particularly bladder and endometrium carcinomas. In this article, we review the relevant features of namitecan, with particular reference to its advantages compared with the two analogues (topotecan and irinotecan) approved for clinical use.
Keywords: Antitumor therapy, Camptothecins, Cellular pharmacology, Clinical studies, Drug resistance, Gimatecan, Namitecan, 7- oxyiminomethyl derivatives, Topoisomerase I, Tumor cells
Current Medicinal Chemistry
Title:Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Volume: 19 Issue: 21
Author(s): G. L. Beretta, V. Zuco, M. De Cesare, P. Perego and N. Zaffaroni
Affiliation:
Keywords: Antitumor therapy, Camptothecins, Cellular pharmacology, Clinical studies, Drug resistance, Gimatecan, Namitecan, 7- oxyiminomethyl derivatives, Topoisomerase I, Tumor cells
Abstract: Camptothecins are still among the most widely prescribed and effective anticancer drugs. Unfortunately, important drawbacks including water insolubility, lactone instability, reversibility of the drug–target interaction, drug resistance and toxicity are responsible for treatment failure and often require suspension of the drug administration itself. In order to overcome such drawbacks, several options in chemical manipulation of natural camptothecin have been explored, and effective compounds have been identified in a novel series of 7- oxyiminomethyl derivatives. Among the compounds of this series, the hydrophilic derivative namitecan (7 (2-aminoethoxy) iminomethyl camptothecin) has been selected for further development. The relevant features of namitecan are: 1) marked cytotoxic potency - likely related to multiple factors, including i) a potent inhibition of topoisomerase I, ii) a persistent stabilization of the cleavable complex, iii) an increased intracellular accumulation, and iv) a peculiar subcellular localization; 2) enhanced lactone stability and favorable pharmacokinetics; 3) remarkable antitumor efficacy in a large panel of human tumor xenografts (including tumor models relatively resistant to topotecan and irinotecan), particularly on squamous cell carcinomas. The clinical development of namitecan is currently ongoing. Namitecan exhibited an acceptable toxicity profile, with neutropenia being the dose-limiting toxic effect, and clinical benefit was appreciable in patients with different tumor types, particularly bladder and endometrium carcinomas. In this article, we review the relevant features of namitecan, with particular reference to its advantages compared with the two analogues (topotecan and irinotecan) approved for clinical use.
Export Options
About this article
Cite this article as:
L. Beretta G., Zuco V., De Cesare M., Perego P. and Zaffaroni N., Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323252
DOI https://dx.doi.org/10.2174/092986712801323252 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Targeting Post-Ejaculation Sperm for Value-Added Contraception
Current Molecular Pharmacology Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts
Current Cancer Drug Targets Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Natural and Synthetic Retinoids: Structural Bases and Biological Effects of Potential Clinical Relevance for the Prevention and Treatment of Infection-Driven Tumors
Anti-Infective Agents in Medicinal Chemistry The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors
Current Bioactive Compounds Non-squamous Tumors of the Oropharynx and Oral Cavity: CT and MR Imaging Findings with Clinical- Pathologic Correlation
Current Medical Imaging Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Ameliorative Effect of α-Tocopherol and Selenium on Effects of Malathion on Plasmatic Biochemical Indices and Lesions in the Liver of Rats
Current Pharmaceutical Analysis Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Antimicrobial and Structural Properties of Metal Ions Complexes with Thiosemicarbazide Motif and Related Heterocyclic Compounds
Current Medicinal Chemistry Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Surgical Options for Management of Malignant Pleural Mesothelioma in the Current Era
Current Respiratory Medicine Reviews Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science